Predictive Oncology Inc. announced that J. Melville (“Mel”) Engle will retire as Chief Executive Officer. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through October 31, 2022. Pursuant to policies regarding leadership succession, the governance committee of POAI's Board of Directors is working with a succession plan to replace Mr. Engle as Chief Executive Officer.

Mr. Engle, 72, has been with POAI since 2016, when he joined the Board of Directors. He was appointed Chairman of the Board in January 2020 and was named Chief Executive Officer in March 2021. He has played an instrumental role in the company's growth as it has evolved as a partner to pharmaceutical and biotech companies involved in oncology drug development.

Under his guidance, Mr. Engle has helped expand the company's offerings to become a suite of solutions along the drug development continuum, from early discovery to clinical trials.